Markus Muttenthaler received his BSc in technical chemistry (2001) and his MSc in organic chemistry and technology (2004) from the Vienna University of Technology. In 2005 he obtained a PhD scholarship to join Paul Alewood’s laboratory at The University of Queensland. He then received training in peptide chemistry and was involved in the discovery, design and development of therapeutics based on bioactive venom peptides. He earned the best PhD thesis award from the Royal Australian Chemical Institute, and the Dean’s award for outstanding higher degree thesis.

As a postdoc, Dr Muttenthaler continued to expand his chemical skills repertoire and developed an interest in oxytocin and vasopressin research. Two Marie Curie Fellowships enabled him to join the Dawson lab at the Scripps Research Institute in California, distinguished for the invention of native chemical ligation, a technique that revolutionised chemical synthesis of proteins, and the Albericio lab at the Institute for Research in Biomedicine Barcelona, renowned for its innovative advancements in combinatorial and peptide chemistry.

In 2015, he was recruited back to IMB as an ARC DECRA fellow to establish his neuropeptide research program. His recent achievements earned him the IMB Industry Fellow Award as well as the prestigious Miklos Bodanszky Award for peptide-based drug research.

Research overview

Research projects

Engagement and impact

Discover more

Researcher biography

Dr Markus Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His research focus is on neuropeptides and the exploration of nature's diversity (i.e. venom peptides) to develop molecular tools, diagnostics and therapeutics. His background in drug discovery, design and development, as well as his interdisciplinary training in the fields of chemistry, molecular biology and pharmacology assist him in the characterisation of these highly potent and selective compounds and allow him to study their interactions with human physiology for medical innovations neuropathic pain, cancer, autism, gastrointestinal disorders and neurodegenerative diseases.